DONALD O. CASTELL, M.D.
This content is PDF only. Please click on the PDF icon to access.
Chronic gastroesophageal reflux, primarily manifested by heartburn, has been estimated to produce daily symptoms in up to 10% of the U. S. population. In the past decade considerable investigative efforts have been applied toward greater understanding of the pathophysiology of this condition and therapy for it. This activity has been fruitful, producing a number of new therapies, some of which are now widely used and some of which have future potential. The medical treatment of reflux esophagitis in the mid-1970s consisted of a few modifications of the patient's lifestyle and the addition of antacids. These approaches, called phase 1 therapy
CASTELL DO. Medical Therapy for Reflux Esophagitis: 1986 and Beyond. Ann Intern Med. ;104:112–114. doi: 10.7326/0003-4819-104-1-112
Download citation file:
Published: Ann Intern Med. 1986;104(1):112-114.
Esophageal Disorders, Gastroenterology/Hepatology, Gastroesophageal Reflux Disease, Peptic Disease, Peptic Ulcer.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use